Data suggests that carriers (heterozygotes) of inactivating variants in SLC34A3 may have increased risk of NL, NC, hypercalciuria, and hypophosphatemia (Dasgupta et al., 2014). The gene discussed is SLC34A3; the disease is Hypercalciuria.